PE20151808A1 - Peptidos terapeuticos - Google Patents
Peptidos terapeuticosInfo
- Publication number
- PE20151808A1 PE20151808A1 PE2015002329A PE2015002329A PE20151808A1 PE 20151808 A1 PE20151808 A1 PE 20151808A1 PE 2015002329 A PE2015002329 A PE 2015002329A PE 2015002329 A PE2015002329 A PE 2015002329A PE 20151808 A1 PE20151808 A1 PE 20151808A1
- Authority
- PE
- Peru
- Prior art keywords
- pyy
- analogs
- therapeutic peptides
- diet
- lean
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57545—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cell Biology (AREA)
Abstract
Se refiere a analogos novedosos del peptido YY (PYY) que tienen un perfil terapeutico mejorado cuando se comparan con PYY nativo de humano. Estos analogos de PYY son utiles en el tratamiento de obesidad, diabetes y otros trastornos metabolicos. De manera preferida, los polipeptidos reducen la ingesta de alimentos en un modelo animal magro y/o de obesidad inducida por dieta en por lo menos 50%
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361818624P | 2013-05-02 | 2013-05-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20151808A1 true PE20151808A1 (es) | 2015-12-16 |
Family
ID=50842285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015002329A PE20151808A1 (es) | 2013-05-02 | 2014-04-30 | Peptidos terapeuticos |
Country Status (20)
Country | Link |
---|---|
US (2) | US20160108098A1 (es) |
EP (1) | EP2992008B1 (es) |
JP (1) | JP2016519130A (es) |
KR (1) | KR20160003848A (es) |
CN (1) | CN105263957A (es) |
AR (1) | AR096162A1 (es) |
AU (1) | AU2014261111B2 (es) |
BR (1) | BR112015027528B1 (es) |
CA (1) | CA2909045C (es) |
CL (1) | CL2015003199A1 (es) |
EA (1) | EA201591839A1 (es) |
ES (1) | ES2732291T3 (es) |
HK (1) | HK1214829A1 (es) |
MX (1) | MX2015015249A (es) |
PE (1) | PE20151808A1 (es) |
RU (1) | RU2015144632A (es) |
SG (1) | SG11201508469YA (es) |
TW (1) | TW201534616A (es) |
UY (1) | UY35548A (es) |
WO (1) | WO2014178018A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3326620T1 (sl) | 2010-12-16 | 2020-07-31 | Novo Nordisk A/S | Trdne sestave, ki vsebujejo agonist GLP-1 in sol N-(8-(2-hidroksibenzoil)amino)kaprilne kisline |
EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
KR20160003848A (ko) * | 2013-05-02 | 2016-01-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 치료용 펩티드 |
JP6602760B2 (ja) * | 2013-11-15 | 2019-11-06 | ノヴォ ノルディスク アー/エス | 選択的なpyy化合物及びその使用 |
JP6629198B2 (ja) | 2013-11-15 | 2020-01-15 | ノヴォ ノルディスク アー/エス | 35位にβ−ホモアルギニン置換を有するHPYY(1−36) |
WO2016124687A1 (en) * | 2015-02-04 | 2016-08-11 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
MA43205A (fr) | 2015-06-12 | 2018-09-19 | Novo Nordisk As | Composés pyy sélectifs et leurs utilisations |
US10808253B2 (en) * | 2015-12-28 | 2020-10-20 | Idemitsu Kosan Co., Ltd. | Peptide tag and tagged protein including same |
JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
AU2018231249A1 (en) | 2017-03-08 | 2019-09-26 | Intarcia Therapeutics, Inc | Apparatus and methods for administration of a nauseogenic compound from a drug delivery device |
MX2020007598A (es) | 2018-02-02 | 2020-09-03 | Novo Nordisk As | Composiciones solidas que comprenden un agonista del peptido similar al glucagon tipo 1 (glp-1), una sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico y un lubricante. |
US10875902B2 (en) | 2018-04-25 | 2020-12-29 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
TW202208410A (zh) | 2018-11-01 | 2022-03-01 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
CA3163507A1 (en) * | 2019-12-04 | 2021-06-10 | The Scripps Research Institute | Peptide conjugates and methods of use |
WO2021212023A1 (en) * | 2020-04-17 | 2021-10-21 | Intarcia Therapeutics, Inc. | Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use |
BR112022025623A2 (pt) | 2020-08-07 | 2023-03-07 | Boehringer Ingelheim Int | Agonistas solúveis de receptores de npy2 |
US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
CN115960258B (zh) * | 2022-09-30 | 2024-01-12 | 广西医科大学附属肿瘤医院 | 一类GLP-1/glucagon/Y2受体三重激动剂及其应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
DK134189D0 (da) | 1989-03-20 | 1989-03-20 | Nordisk Gentofte | Insulinforbindelser |
JP3262329B2 (ja) | 1990-01-24 | 2002-03-04 | アイ. バックレイ,ダグラス | 糖尿病治療に有用なglp―1アナログ |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5612052A (en) | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
CA2262647C (en) | 1996-08-08 | 2007-12-04 | Amylin Pharmaceuticals, Inc. | Methods for regulating gastrointestinal motility |
DK1019077T4 (da) | 1997-08-08 | 2011-03-07 | Amylin Pharmaceuticals Inc | Hidtil ukendte exendinagonistforbindelser |
US6004573A (en) | 1997-10-03 | 1999-12-21 | Macromed, Inc. | Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
US6117949A (en) | 1998-10-01 | 2000-09-12 | Macromed, Inc. | Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties |
EP1032587B2 (en) | 1997-11-14 | 2013-03-13 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
EP1066314B1 (en) | 1997-11-14 | 2007-12-26 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
WO1999040788A1 (en) | 1998-02-13 | 1999-08-19 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and glp-1 |
EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
KR100902625B1 (ko) | 2000-08-15 | 2009-06-15 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 마이크로입자 |
JP2005508324A (ja) * | 2001-09-24 | 2005-03-31 | インペリアル カレッジ イノベーションズ リミテッド | 摂食行動の修正 |
US8603969B2 (en) * | 2004-02-11 | 2013-12-10 | Amylin Pharmaceuticals, Llc | Pancreatic polypeptide family motifs and polypeptides comprising the same |
WO2006066024A2 (en) * | 2004-12-13 | 2006-06-22 | Amylin Pharmaceuticals, Inc. | Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
CA2577821A1 (en) * | 2004-09-24 | 2006-04-06 | Merck & Co., Inc. | Combination therapy for the treatment of obesity |
PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
GB0504857D0 (en) * | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
WO2007112069A2 (en) * | 2006-03-23 | 2007-10-04 | Amylin Pharmaceuticals, Inc. | Endothelin and endothelin receptor agonists in the treatment of metabolic diseases |
WO2011039096A1 (en) | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
WO2011050008A2 (en) * | 2009-10-19 | 2011-04-28 | Amylin Pharmaceuticals, Inc. | Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders |
GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
JO3131B1 (ar) | 2010-04-27 | 2017-09-20 | Glaxosmithkline Llc | مركبات كيميائية |
US8927687B2 (en) * | 2010-07-09 | 2015-01-06 | Amylin Pharmaceuticals, Llc | Microcrystalline Y receptor agonists |
GB201101459D0 (en) * | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
KR20160003848A (ko) * | 2013-05-02 | 2016-01-11 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 치료용 펩티드 |
JP6602760B2 (ja) * | 2013-11-15 | 2019-11-06 | ノヴォ ノルディスク アー/エス | 選択的なpyy化合物及びその使用 |
-
2014
- 2014-04-30 KR KR1020157034300A patent/KR20160003848A/ko not_active Application Discontinuation
- 2014-04-30 RU RU2015144632A patent/RU2015144632A/ru not_active Application Discontinuation
- 2014-04-30 AU AU2014261111A patent/AU2014261111B2/en active Active
- 2014-04-30 PE PE2015002329A patent/PE20151808A1/es not_active Application Discontinuation
- 2014-04-30 WO PCT/IB2014/061123 patent/WO2014178018A1/en active Application Filing
- 2014-04-30 JP JP2016511159A patent/JP2016519130A/ja active Pending
- 2014-04-30 UY UY0001035548A patent/UY35548A/es not_active Application Discontinuation
- 2014-04-30 TW TW103115659A patent/TW201534616A/zh unknown
- 2014-04-30 BR BR112015027528-1A patent/BR112015027528B1/pt active IP Right Grant
- 2014-04-30 CA CA2909045A patent/CA2909045C/en active Active
- 2014-04-30 SG SG11201508469YA patent/SG11201508469YA/en unknown
- 2014-04-30 US US14/888,085 patent/US20160108098A1/en not_active Abandoned
- 2014-04-30 MX MX2015015249A patent/MX2015015249A/es unknown
- 2014-04-30 EA EA201591839A patent/EA201591839A1/ru unknown
- 2014-04-30 ES ES14727241T patent/ES2732291T3/es active Active
- 2014-04-30 US US14/265,831 patent/US9441023B2/en active Active
- 2014-04-30 AR ARP140101793A patent/AR096162A1/es unknown
- 2014-04-30 EP EP14727241.3A patent/EP2992008B1/en active Active
- 2014-04-30 CN CN201480024836.3A patent/CN105263957A/zh active Pending
-
2015
- 2015-10-30 CL CL2015003199A patent/CL2015003199A1/es unknown
-
2016
- 2016-03-09 HK HK16102709.0A patent/HK1214829A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2992008A1 (en) | 2016-03-09 |
KR20160003848A (ko) | 2016-01-11 |
US9441023B2 (en) | 2016-09-13 |
WO2014178018A1 (en) | 2014-11-06 |
HK1214829A1 (zh) | 2016-08-05 |
CL2015003199A1 (es) | 2016-05-06 |
SG11201508469YA (en) | 2015-11-27 |
AR096162A1 (es) | 2015-12-09 |
CA2909045A1 (en) | 2014-11-06 |
CA2909045C (en) | 2022-12-06 |
BR112015027528B1 (pt) | 2023-02-14 |
AU2014261111A1 (en) | 2015-11-19 |
TW201534616A (zh) | 2015-09-16 |
EP2992008B1 (en) | 2019-04-10 |
ES2732291T3 (es) | 2019-11-21 |
EA201591839A1 (ru) | 2016-05-31 |
JP2016519130A (ja) | 2016-06-30 |
MX2015015249A (es) | 2016-02-09 |
US20160108098A1 (en) | 2016-04-21 |
RU2015144632A (ru) | 2017-06-07 |
CN105263957A (zh) | 2016-01-20 |
UY35548A (es) | 2014-11-28 |
AU2014261111B2 (en) | 2017-03-16 |
US20140329742A1 (en) | 2014-11-06 |
BR112015027528A2 (pt) | 2017-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20151808A1 (es) | Peptidos terapeuticos | |
SV2017005594A (es) | Compuestos co-agonistas de glucagon y glp-1 | |
CY1122539T1 (el) | Αναλογα γλυκαγονης | |
CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
ECSP19046893A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
MX2023010869A (es) | Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos. | |
CO7400885A2 (es) | Análogos de glucagón | |
BR112016022465A2 (pt) | agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4 | |
CU20140034A7 (es) | Proteínas de fusión para tratar trastornos metabólicos | |
UY34859A (es) | Análogos peptídicos de la exendina 4. | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
MX2019013536A (es) | Compuestos para el tratamiento de los trastornos de resistencia sistemica a la insulina y el uso de los mismos. | |
BR112018067731A2 (pt) | coagonistas de glucagon e glp-1 para o tratamento de obesidade | |
BR112017025000A2 (pt) | tratamento de hipoglicemia pós-bariátrica com exendina (9-39) | |
BR112018010155A8 (pt) | segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca | |
EA201992562A1 (ru) | Пептиды для лечения сахарного диабета | |
BR112015018265A2 (pt) | Composições nutricionais contendo um componente peptídico com propriedades estimulantes de adiponectina e utilizações das mesmas | |
EA201890163A1 (ru) | Композиция фолликулостимулирующего гормона млекопитающего с повышенной стабильностью | |
BR112015017909A2 (pt) | redução do risco de doença autoimune | |
CY1120861T1 (el) | Συνθεσεις και μεθοδοι για θεραπευτικη αγωγη διαβητη τυπου 1 | |
AR112541A1 (es) | Composición para estimulación ovárica controlada con hef recombinante | |
ECSP15009978A (es) | Análogos de glucagón |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |